SEALSQ leads $10 million PIPE investment in WISeSat.Space
Bitget2026/10/06 13:30SEALSQ led a USD 10 million PIPE in WISeSat.Space, closing Oct. 1, 2026 alongside the business combination. Subscription price set at USD 10.79 per share, matching the redemption price. Price-protection clause could trigger issuance of up to 1,073,216 additional WISeSat ordinary shares if VWAP falls below USD 10.79. Proceeds earmarked for next-generation satellites, integrating post-quantum cryptography across space, ground, and user segments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SEALSQ Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060930PRIMZONEFULLFEED9840503) on October 06, 2026, and is solely responsible for the information contained therein.
- SEALSQ led a USD 10 million PIPE in WISeSat.Space, closing Oct. 1, 2026 alongside the business combination.
- Subscription price set at USD 10.79 per share, matching the redemption price.
- Price-protection clause could trigger issuance of up to 1,073,216 additional WISeSat ordinary shares if VWAP falls below USD 10.79.
- Proceeds earmarked for next-generation satellites, integrating post-quantum cryptography across space, ground, and user segments.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.